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We present the case of a patient with a deep vein thrombosis (DVT) who failed rivaroxaban therapy. Our patient initially presented
with left lower extremity edema, erythema, and pain. Hewas subsequently started on rivaroxaban therapy for a combined treatment
period of 12 months, during and after which he persisted to have evidence of a DVT. The patient’s prescribed drug regimen was
changed from rivaroxaban to warfarin, which demonstrated a rapid resolution of theDVTs as determined by ultrasound assessment
of our patient’s lower extremity veins. Rivaroxaban, a factor Xa inhibitor, is a well-known oral anticoagulant that is used for a variety
of indications and has become a mainstay in the treatment of deep vein thrombosis. With the introduction and emergence of this
medication in the clinic, postmarketing reports of efficacy or lack thereof are important to review. In conclusion, we anticipate that
it is likely that there are other patients with DVTs who may not respond to rivaroxaban and for whom alternative anticoagulation
therapies should be explored.
1. Introduction
Rivaroxaban (Xarelto) is a novel oral anticoagulant that
inhibits platelet activation and fibrin clot formation via direct,
selective, and reversible inhibition of factor Xa in both the
intrinsic and extrinsic coagulation pathways. Factor Xa, as
part of the prothrombinase complex consisting also of factor
Va, calcium ions, factor II, and phospholipid, catalyzes the
conversion of prothrombin to thrombin. Thrombin both
activates platelets and catalyzes the conversion of fibrinogen
to fibrin. At this time, factor Xa inhibitors are emerging as
a popular alternative to the use of vitamin K antagonists
(VKA) or warfarin therapy because factor Xa inhibitors do
not require international normalized ratio (INR) testing nor
specific dietary restrictions. The indications for rivaroxaban
therapy include reduction in the risk of stroke and systemic
embolism in patients with nonvalvular atrial fibrillation,
treatment of deep vein thrombosis (DVT), treatment of pul-
monary embolism (PE), reduction in the risk of recurrence
of DVT and of PE after a 6-month trial for the treatment for
DVT and/or PE, or prophylaxis of DVT (which may lead to
PE in patients undergoing knee replacement or hip replace-
ment surgery) [1]. Major contraindications include active
pathological bleeding and severe hypersensitivity reaction
such as anaphylaxis [1]. Rivaroxaban is currently widely rec-
ommended as amainstay treatment forDVT [2]. Aminimum
of three months of anticoagulation with medications such
as rivaroxaban are recommended in those with unprovoked
DVT or recurrent DVT or provoked with minor risk factors
for DVT [2]. If treatment is successful and the thrombus
resolves, some patients may still require indefinite treatment
[2]. Unfortunately, when factor Xa inhibitors fail, the alter-
natives in an outpatient setting are to change therapy to
low molecular weight heparin and/or warfarin therapies [2].
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Indeed, the standard for both prevention and treatment for
over 60 years has been vitamin k antagonists like warfarin
(Coumadin, Jantoven, and Marevan), phenprocoumon,
and acenocoumarol; however, VKA therapy is inconvenient
due in part to its increased risk of adverse events such
as bleeding, dietary restrictions, and the need for regular
blood monitoring, thereby making it a less desirable option
[2].
In addition to not requiring dietary restrictions nor fre-
quent INR evaluations, rivaroxaban has other advantages
such as rapid absorption and almost 100% bioavailability
when taken with food (at specific doses) [3] and has been
shown, in some studies, to be noninferior to enoxaparin/
VKA—the current standard of care for venous thromboem-
bolism [4]. On the other hand, rivaroxaban’s disadvantages
have been documented as well. The major disadvantages
include internal bleeding, particularly gastrointestinal bleed-
ing [5], as well as documented cases in which thromboem-
bolisms do not completely resolve [6, 7].
2. Case Presentation
The patient in this case report is a 65-year-old white male,
with a past medical history significant for mild depression
and subclinical hypothyroidism,who presented in 2015with a
primary complaint of 3 days of left lower extremity pain, ery-
thema, and edema. At the time of the visit, he also complained
of dizziness of 2-day duration which was not related to
changes of position.The severity of this symptomwasmild to
moderate, and no other associated symptoms were noted. He
reported being very sedentary and experienced some tingling
of the right foot. The patient denied chest pain, shortness
of breath, palpitations, or syncope. He did not monitor his
blood pressure at home, nor did he follow any exercise or
diet programs. He has no known drug allergies, and his
drug regimen at initial presentation included escitalopram
20 milligrams every other day for mild depression (which
was being tapered off), as well as fiber supplements and daily
multivitamins.Overall, the patientwas noted to havemultiple
risk factors for coronary artery disease includingmale gender,
age, sedentary lifestyle, stress, and tobacco use.
On physical examination, the patient was reported as a
well-developed, well-nourished male with a BMI of 23.1 and
body weight of 79.4 kilograms. The patient’s neck was supple
with no jugular venous distention. A left carotid bruit was
audible, carotid pulses were +2/2, and there was a normal
carotid artery upstroke bilaterally. His lungs were clear to
auscultation bilaterally without wheezes or rhonchi. His
cardiovascular exam revealed a regular heart rate and rhythm.
His cardiac point of maximal impulse was at the left fifth
intercostal space in the mid-clavicular line. Normal cardiac
S1 and S2 sounds were noted with physiologic splitting of S2.
Nomurmurs, thrills, rubs, gallops, or clicks were appreciated.
Pulses in the extremities were 2+ throughout bilaterally at
the time of presentation, and no cyanosis or clubbing was
noted. Mild varicose veins in the distal lower extremities
bilaterally were noted. Evidence of left lower extremity pain,
erythema, and edema were noted. An abridged mental status
exam revealed a cooperative patient well oriented to time,
place, and person, without evidence of psychotic features.The
patient’s recall was within normal limits.
Given these findings, the patient underwent an ultra-
sound study that confirmed a left femoral vein thrombus, and
he was started on rivaroxaban therapy. In accord with current
recommendations for rivaroxaban therapy, the patient was
started on rivaroxaban at 15 milligrams PO twice daily for
3 weeks and then continued at 20 milligrams PO daily
for 6 months. Upon initiation of rivaroxaban, aspirin 81
milligrams POdaily was added to his regimen. DVTpresence
was monitored, and rivaroxaban therapy was eventually
discontinued after a total of one year (per protocol [2]) and
aspirin was continued for an additional 2 months. When
serial follow-up ultrasounds continued to show persistent
thrombi in the femoral and popliteal veins, he was then
restarted on rivaroxaban therapy for another 2 months at
20mg daily. After this second challenge with rivaroxaban,
a repeat ultrasound again showed a persistent DVT. The
patient was then bridged to warfarin therapy, continuing
rivaroxaban at 20mg daily and adding warfarin 5mg daily
with an INR goal of 2.0–3.0. Thereafter, his INR goals were
met by adjusting his warfarin dose weekly. After 5 days of
bridging, rivaroxaban was discontinued.
The patient was maintained on warfarin 7.5 milligrams
alternating with 5 milligrams on alternate days PO (dosing
varies by week per INR) in addition to escitalopram, fiber
supplementation, and multivitamins, as mentioned earlier.
This regimen was well tolerated by the patient and without
complication.
In review, after initiation of rivaroxaban therapy, the
patient continued to be symptomatic; therefore, we continued
to monitor his DVTs to assess his progression. A Siemens
ACUSON Cypress ultrasound system was used to perform
ultrasonography of his lower extremity which revealed
thrombus in his left mid-superficial femoral vein (SFV). The
ultrasound assessments began six days after initiation of
rivaroxaban therapy (Figures 1(a)–1(d)) and then again at 9
months.Then, after one year of rivaroxaban and aspirin treat-
ment, followed by 2 months of aspirin therapy alone, another
ultrasound was performed which continued to demon-
strate thrombus presence. Finally, after bridging to warfarin
therapy, another ultrasound was performed which demon-
strated vast improvements (see Figures 2(a)–2(e)).
Figures 1(a)–1(d) demonstrated our initial/baseline ultra-
sound findings which correspond to six days following ini-
tiation of rivaroxaban therapy. The right mid-SFV appeared
patent without compression (Figure 1(a)) and fully collapsed
upon compression (Figure 1(b)), indicating no presence of
thrombi. The left SFVmeasured 8.3 millimeters, before com-
pression with the ultrasound transducer (Figure 1(c)), and
manual compression of the vessel measured 8.2 millimeters
(Figure 1(d)), indicating the presence of a thrombus.
Over a period of approximately one year of treatmentwith
rivaroxaban, the ultrasound measurements demonstrated a
general downward trend in the size of the thrombi which
were followed over approximately one year of treatment with
rivaroxaban, but a complete resolution in half of the vessels
followed was not detected. The left common femoral vein
(CFV) DVT resolved at the 9th-month mark (Figure 2(a)),
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Figure 1: Lower extremity ultrasound findings upon initial evaluation. (a) Uncompressed right superficial femoral vein patent. (b)
Compressed right superficial femoral vein completely collapsed. (c) Uncompressed left superficial femoral vein at 8.3mm. (d) Compressed
left superficial femoral vein at 8.2mm.
and the left proximal SFV thrombosis resolved at the one-year
mark (Figure 2(b)). The more distal thrombi (left mid-SFV
and distal SFV) waxed and waned, but these were generally
stable at the one-year assessment. When the patient was
switched to warfarin treatment, there was an approximately
13% improvement in the left distal SFV and a 20% improve-
ment of the left mid-SFV in a period of just 16 days (Figures
2(c) and 2(d)). The most drastic change in percent occlusion
was of the left popliteal vein, which underwent a rapid and
complete resolution of the thrombosis within 16 days of
warfarin treatment after a slow but steady decline in the size
of the thrombuswith rivaroxaban therapy alone (Figure 2(e)).
3. Discussion and Conclusion
This case is of interest because a widely used and approved
pharmacologic treatment of DVT did not perform as
expected in this patient. A thorough literature review revealed
little in the way of reports of rivaroxaban failure in the
treatment of DVT, although a few case reports in which
potential rivaroxaban failure is noted have emerged recently
[6, 7]. Postmarketing surveillance is clearly an important
factor in the further development, safety, and efficacy of any
novel drug. Since the initial FDA approval of rivaroxaban in
July 2011, this drug has been indicated for many uses and is
widely recommended in current clinical practice [8].
Heparin and vitamin K antagonist have at times been
shown to fail in the treatment of thrombi [9–11]. The recent
addition of factor Xa inhibitors to anticoagulant agents is
not without fault (i.e., failure, bleeding, and lack of reversal
agents), as demonstrated in this case report and other papers
[6, 7, 12].The risk factors for failure of anticoagulation therapy
are vast and vary frompatient to patient; pharmacodynamics,
pharmacokinetics, metabolism, and elimination all have a
hand in how a drug interacts in a given patient and are further
discussed below [13–15]. The patient discussed in our case
does not seem to have any of these risk factors as noted from
his normal liver function tests and creatinine clearance.
Another lab value of interest is the D-dimer level. The
patient’s D-dimer valuewas elevated to 4160 ng/ml fibrinogen
equivalent units or FEU (normal is less than 500 ng/ml FEU)
upon initiation of rivaroxaban treatment. The D-dimer level
was noted to decrease over time with rivaroxaban alone;
however, the value never normalized (even after more than
one year of treatment). Over approximately 5 months of war-
farin therapy alone, the D-Dimer values steadily normalized
(190 ng/ml FEU).
Although factor Xa inhibitors are quite popular, there
are cases emerging of its rare adverse effects (i.e., exsan-
guination), especially in patients with hypertension, heart
failure, coronary heart disease, and impaired renal and/or
hepatic function and those with certain types of cancers [16].
Animalmodels are exposing othermechanisms that affect the
efficacy of rivaroxaban; in one mouse model, rivaroxaban’s
anticoagulant effect was augmented by angiotensin II [17].
The pathophysiology for the potential failure of rivaroxa-
ban therapy in the treatment of DVT is poorly understood.
However, drug metabolism may play a significant role.
The physiologic metabolism of rivaroxaban is severalfold,
including oxidative degradation of the morpholinone moiety
4 Case Reports in Cardiology
Percentage of le CFV occluded versus time and treatment
0
20
40
60
80
100
Pe
rc
en
t o
cc
lu
de
d
6 days of
Xarelto
9 months of
Xarelto
1 year of xarelto
followed by 2-
16 days
of warfarin
Time and treatment method
month break
(a)
0
20
40
60
80
100
Percentage of le proximal SFV occluded versus time and treatment
Pe
rc
en
t o
cc
lu
de
d
6 days of
Xarelto
9 months of
Xarelto
1 year of xarelto
followed by 2-
16 days
of warfarin
Time and treatment method
month break
(b)
Percentage of le mid SFV occluded versus time and treatment
0
50
100
150
Pe
rc
en
t o
cc
lu
de
d
6 days of
Xarelto
9 months of
Xarelto
1 year of xarelto
followed by 2-
16 days
of warfarin
Time and treatment method
month break
(c)
Percentage of le distal SFV occluded versus time and treatment
0
20
40
60
80
100
Pe
rc
en
t o
cc
lu
de
d
6 days of
Xarelto
9 months of
Xarelto
1 year of xarelto
followed by 2-
16 days
of warfarin
Time and treatment method
month break
(d)
Percentage of le popliteal vein occluded versus time and treatment
0
20
40
60
80
100
Pe
rc
en
t o
cc
lu
de
d
6 days of
Xarelto
9 months of
Xarelto
1 year of xarelto
followed by 2-
16 days
of warfarin
Time and treatment method
month break
(e)
Figure 2: Left lower extremity vein percent occlusion. (a) Progression of vein occlusion of left CFV. (b) Progression of vein occlusion of left
proximal SFV. (c) Progression of vein occlusion of left mid-SFV. (d) Progression of vein occlusion of left distal SFV. (e) Progression of vein
occlusion of left popliteal vein.
as the major pathway and hydrolysis of the central amide
bond and of the lactam amide bond in themorpholinone ring
as the minor pathways, all of which occur within hepatocytes
and liver microsomes [13]. Any change in the metabolism of
any of these pathways would lead to a change in the efficacy
of the drug itself. Furthermore, the main metabolite of
rivaroxaban is excreted both renally and fecally via the biliary
system, and malfunctioning of these pathways could also
lead to a change in the efficacy of rivaroxaban. Rivaroxaban
is also well known to be metabolized by the cytochrome
P450 isoenzyme CYP3A4 and binds to P-glycoprotein, hence
leading to risks of pharmacokinetic interactions that may
alter its anticoagulant properties [14]. Furthermore, it is
notable that rivaroxaban has a terminal half-life of only 5–9
hours, yet it is generally recommended to be taken at 20mg
PO once a day after an initial dosing period at 15mg PO
twice daily. In view of such relatively rapid elimination, high,
early peaks of rivaroxaban could increase the risk of bleeding
and low troughs could result in suboptimal anticoagulation. It
will be important to determine if a better rivaroxaban dosing
regimen is required to address its unique pharmacokinetic
profile [15]. One study suggests a method that measures
rivaroxaban’s activity level in individual patients, which can
be used to compare clinical variable and patient outcomes,
leading to a more customizable treatment plan and dosing
regimen [18].
With regard to this case report on thrombus resolution
after warfarin therapy, further work-up is warranted to
discover the lack of the expected response to primary rivarox-
aban treatment; these diagnostics may include a throm-
bophilia panel and rivaroxaban serum levels to determine
genetic risk factors and compliance, respectively. The patient
did not present with any apparent hepatic or renal insuffi-
ciency based on normal liver function tests and creatinine
levels on initial examination, as mentioned previously. Renal
function has been shown to have a hand in the dosing of
factor Xa inhibitors [19]. Factors that may be affecting this
drug’s efficacy could be lack of proper compliance, various
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hypercoagulable states, or certain mutations that can cause
undesirable metabolism of rivaroxaban [20]. Selective sero-
tonin reuptake inhibitors have been known to cause platelet
aggregation/hypercoagulable states and potentially lead to
thrombus formation and even cause pulmonary embolism
[21].
Because of the threat of a pulmonary embolism from a
DVT, it is important to have considered other factors/features
that may be related to thrombi. A negative D-dimer lab value
can help exclude the possibility of a PE [22]; in the case of
our patient, initially, his D-dimer value was elevated, as noted
above, and normalized after some time with warfarin therapy
alone; this was not unexpected, as the protective effects of
warfarin in the case of DVT/pulmonary embolism have been
well documented [23].
Another feature of DVTs to consider is whether the
thrombi noted in our patient are persistent or recurrent. Due
to the location, initial size, and downtrending progression
of the thrombi, we strongly believe that our patient had
persistent thrombi. Assessing for persistent versus recurrent
thrombi would be quite difficult as a thrombus can form in as
little as 4 hours [24].
Although extremes of bodyweight (<50 kg or>120 kg) are
not reported to significantly influence rivaroxaban’s effects,
the International Society on Thrombosis and Haemostasis
(ISTH) 2016 guideline suggests avoiding the use of rivarox-
aban (and other direct oral anticoagulants) in patients with a
BMI > 40 kg/m2 or body weight > 120 kg due to the lack of
clinical data in this population (ISTH) [25].
In clinical practice, it may be best to choose between
available anticoagulant drugs on a case-by-case basis [26]. It
will be important to take into account patient preferences,
monitoring constraints and difficulty controlling the INR, the
risk of bleeding, drug interactions, and the cost of treatment
[27]. In light of this case report, we acknowledge novel
oral anticoagulants, such as rivaroxaban, to be an important
contribution tomany formularies as they have been beneficial
to the vast majority of patients who require anticoagulation;
this case report is merely intended to highlight a noted
anomaly to be taken into consideration for future practice.
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